INS and Hypoglycemia: The glycemic target was the maintenance of baseline HbA1c to avoid an excessive risk of hypoglycemia, which was overall maintained during the entire study period, but a small, yet statistically significant, reduction of 1.4 mmol/mol during treatment with insulin analogs in the maintenance periods (p < 0.05) (Pedersen-Bjergaard et al., 2014a).